Home » Newsletters » BioWorld Science

BioWorld Science

May 19, 2016

View Archived Issues

Daiichi Sankyo reviews events of fourth quarter of fiscal 2015

Ono Pharmaceutical enters into option agreement with IDAC Theranostics for IT-1208

Theranexus presents promising results for TNH-102 in excessive daytime sleepiness

Patient-derived models could facilitate discovery of drugs for NSCLC harboring exon-20 insertions

Novel experimental mouse models of Brazilian Zika virus infection

Evestra describes first-in-class leukemia inhibitory factor inhibitor

Novel, dual IDO1/TDO inhibitor RG-70099 is active in vivo

PfSPZ Vaccine provides durable protection against malaria

Indivior announces dopamine receptor inhibitors

Genoscience Pharma patents antineoplastic compounds

Pfizer presents TRPA1 antagonists

Merck & Co. announces ROMK channel blockers

Karus Therapeutics introduces histone deacetylase inhibitors

Agios and Celgene form new metabolic immuno-oncology collaboration

Merck & Co. initiates phase I study of MK-4280 in patients with advanced solid tumors

Oramed's phase IIb trial of ORMD-0801 meets primary endpoints

ANAVEX 2-73 reduces epileptic spasms in infant rats

FDA approves Tecentriq and complementary diagnostic for metastatic urothelial carcinoma

Monaleesa-2 trial of ribociclib achieves meaningful improvement in PFS

Lynparza does not achieve primary OS endpoint in phase III GOLD trial

Phase I cohort results for mirvetuximab soravtansine in FRalpha-positive ovarian cancer

Novartis creates two new divisions, Novartis Pharmaceuticals and Novartis Oncology

GeoVax Labs plans new trial of HIV vaccine GOVX-B11

Gilead Sciences completes acquisition of Nimbus Apollo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...